Law360, New York (April 29, 2011, 4:25 PM ET) -- Drug and medical device maker Eli Lilly & Co. said Friday it was in advanced discussions with the U.S. Securities and Exchange Commission to resolve an investigation into potential violations of the Foreign Corrupt Practices Act.
Lilly's announcement of the negotiations to resolve bribery allegations against its foreign subsidiaries in an SEC quarterly report comes less than a month after drug and device giant Johnson & Johnson paid a total of $78 million to resolve allegations of bribery by subsidiaries in Poland and other countries levied...
Lilly, SEC Push Toward Deal In FCPA Probe
To view the full article, take a free trial now.
